Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) EBT (2016 - 2025)

Historic EBT for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $300.0 million.

  • Teva Pharmaceutical Industries' EBT rose 22145.75% to $300.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 51228.57%. This contributed to the annual value of $1.2 billion for FY2025, which is 19524.92% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its EBT stood at $300.0 million for Q4 2025, which was up 22145.75% from $646.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBT ranged from a high of $646.0 million in Q3 2025 and a low of -$1.8 billion during Q4 2023
  • Its 5-year average for EBT is -$214.8 million, with a median of -$55.5 million in 2021.
  • Its EBT has fluctuated over the past 5 years, first soared by 70392.16% in 2021, then plummeted by 77430.56% in 2022.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBT stood at -$175.0 million in 2021, then tumbled by 577.14% to -$1.2 billion in 2022, then crashed by 48.1% to -$1.8 billion in 2023, then surged by 85.93% to -$247.0 million in 2024, then surged by 221.46% to $300.0 million in 2025.
  • Its EBT stands at $300.0 million for Q4 2025, versus $646.0 million for Q3 2025 and $203.0 million for Q2 2025.